CN112022734A - Eye tightening essence and preparation method thereof - Google Patents
Eye tightening essence and preparation method thereof Download PDFInfo
- Publication number
- CN112022734A CN112022734A CN202011012499.XA CN202011012499A CN112022734A CN 112022734 A CN112022734 A CN 112022734A CN 202011012499 A CN202011012499 A CN 202011012499A CN 112022734 A CN112022734 A CN 112022734A
- Authority
- CN
- China
- Prior art keywords
- eye
- mixture
- tightening essence
- mass
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 87
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 49
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- 229920001184 polypeptide Polymers 0.000 claims abstract description 48
- 239000000419 plant extract Substances 0.000 claims abstract description 46
- 239000000284 extract Substances 0.000 claims abstract description 44
- 241001519524 Kappaphycus alvarezii Species 0.000 claims abstract description 23
- 241001424341 Tara spinosa Species 0.000 claims abstract description 23
- IHRKJQSLKLYWBQ-QKDODKLFSA-N (2s)-2-[[(2s)-1-[(2s)-5-amino-2-[[2-(hexadecanoylamino)acetyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O IHRKJQSLKLYWBQ-QKDODKLFSA-N 0.000 claims abstract description 20
- BYUQATUKPXLFLZ-UIOOFZCWSA-N CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 Chemical compound CCCCCCCCCCCCCCCC(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(O)=O)CC1=CN=CN1 BYUQATUKPXLFLZ-UIOOFZCWSA-N 0.000 claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 20
- 229940093441 palmitoyl oligopeptide Drugs 0.000 claims abstract description 20
- 229940094946 palmitoyl tetrapeptide-7 Drugs 0.000 claims abstract description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 60
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 42
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 22
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 22
- 229920006037 cross link polymer Polymers 0.000 claims description 22
- 150000002148 esters Chemical class 0.000 claims description 22
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 21
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 21
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 21
- 229960000281 trometamol Drugs 0.000 claims description 21
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 20
- 229920002125 Sokalan® Polymers 0.000 claims description 20
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 20
- 229960001631 carbomer Drugs 0.000 claims description 20
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 20
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 18
- KIUVQMGRTDPAFR-UHFFFAOYSA-N benzoic acid 2-hydroxy-2-phenylpropanamide Chemical compound C(C1=CC=CC=C1)(=O)O.OC(C(=O)N)(C)C1=CC=CC=C1 KIUVQMGRTDPAFR-UHFFFAOYSA-N 0.000 claims description 18
- 239000008367 deionised water Substances 0.000 claims description 18
- 229910021641 deionized water Inorganic materials 0.000 claims description 18
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 17
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 17
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 17
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 6
- 235000005152 nicotinamide Nutrition 0.000 claims description 5
- 239000011570 nicotinamide Substances 0.000 claims description 5
- 229960003966 nicotinamide Drugs 0.000 claims description 5
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000007599 discharging Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000007689 inspection Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002562 thickening agent Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 230000002087 whitening effect Effects 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 239000003002 pH adjusting agent Substances 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 230000037303 wrinkles Effects 0.000 abstract description 11
- 239000002085 irritant Substances 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 231100000021 irritant Toxicity 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 230000007774 longterm Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 30
- 230000000052 comparative effect Effects 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- 229920000855 Fucoidan Polymers 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000004889 Interleukin-6 Human genes 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000003344 environmental pollutant Substances 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- 229940100601 interleukin-6 Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 231100000719 pollutant Toxicity 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- 206010051788 Sticky skin Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9717—Rhodophycota or Rhodophyta [red algae], e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses an eye tightening essence and a preparation method thereof, and belongs to the field of daily chemicals; the eye tightening essence comprises the following components in percentage by mass: 0.1-1% of plant extract and 1-5% of polypeptide mixture; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. The eye-tightening essence disclosed by the invention is safe and non-irritant, the plant extract and the polypeptide are compounded, and a specific dosage proportion is selected, so that a synergistic effect is achieved in the aspect of tightening effect, and meanwhile, the eye-tightening essence has a good instant and long-acting wrinkle removing function, the dosage of peptides in cosmetics is greatly reduced, the safety of long-term use of the eye-tightening essence is further improved, and the stability of a cosmetic system can be effectively ensured.
Description
Technical Field
The invention belongs to the field of daily chemicals, and relates to a skin care product, in particular to an eye tightening essence and a preparation method thereof.
Background
Consumers with relaxed, relaxed skin, loss of elasticity, wrinkle removal and lack of gloss have been looking for solutions to youthful and healthy skin, and a recent consumer study has shown that there is increasing concern about environmental damage, especially pollution. Due to industrial activities and urban expansion, we are constantly exposed to allergens, irritant molecules or fine particles. Particulate matter emitted by motor vehicles has a devastating effect on health. In addition to its effects on the respiratory system, it causes significant damage to the skin by accelerating skin aging, manifested by the appearance of wrinkles and pigmented spots. With the continuous and deep understanding of the importance and necessity of cosmetic protection, the demand of the cosmetic market is increasing, and eye products with safety, high efficiency and broad spectrum become the focus of attention of people.
However, existing eye products do not well meet consumer needs:
(1) the use comfort of most products needs to be improved: the addition amount of some film forming agents and fillers is large, and the problems of mud rubbing, sticky skin feel and the like are caused when the addition amount is increased;
(2) safety: because eye skin is sensitive, the components in the existing formula are easy to cause allergy and irritation reaction of sensitive skin, so that the problems of skin barrier damage and the like are caused;
(3) the effect problem is as follows: conopeptides and polypeptides have short-term wrinkle-removing maintenance time, collagen can remove wrinkles for a long time, but has no obvious short-term effect, and the collagen cannot be directly absorbed by skin, so that a corresponding small molecular structure can be obtained by complex treatment.
Disclosure of Invention
The invention aims to provide the eye tightening essence with good skin feeling, safety and remarkable effect aiming at the defects of the prior art. Meanwhile, the invention also provides a preparation method of the eye tightening essence.
In order to achieve the purpose, the invention adopts the technical scheme that: the eye tightening essence comprises the following components in percentage by mass: 0.1-1% of plant extract and 1-5% of polypeptide mixture; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The plant extract is purchased from SILAB company, and the product model is FILLEXIL; wherein the Caesalpinia spinosa (CAESALPINIA SPINOSA) fruit extract is a natural biopolymer.
Kappaphycus ALVAREZII (Kappaphycus ALVAREZII) is an extract of algae, contains various vitamins and colloids, and is effective in keeping moisture and water, maintaining skin elasticity, and making skin smooth and elastic. The kappaphycus alvarezii extract and the tara spinosa fruit extract mutually penetrate through each other through the IBPN technology to form a biological polymerization network, have dense molecular network tissues, remarkable biomechanical properties and superior film forming capability, can form a layer of defensive, flexible and non-blocking film on the surface of skin, and form a non-blocking barrier like a second layer of skin to resist pollutants, irritants and allergens, protect the natural barrier function of the skin and prevent the skin from being degraded caused by mechanical stress; and can smooth the micro-fluctuation of the skin of the face (body), quickly and durably fade wrinkles and tighten the skin.
The palmitoyl tripeptide-1 can promote the generation of skin collagen, make the facial skin plump and elastic, improve the water content and moisture retention of the skin, improve the skin color, effectively reduce fine lines and wrinkles of the skin, enhance the firming feeling and glossiness of the skin and make the skin feel soft, smooth and greasy.
Interleukins are liable to cause inflammatory reactions leading to degradation of ECM active substances in the intercellular substance leading to wrinkles and loss of elastic stability; palmitoyl tetrapeptide-7 can effectively reduce the production of interleukin-6 (IL-6) in keratinocytes and fibroblasts, thus effectively protecting the skin and delaying aging.
The plant extract and the polypeptide mixture are compounded, and the proportion of the plant extract and the polypeptide mixture is optimized, so that the synergistic wrinkle-removing cream has the effects of removing wrinkles instantly and removing wrinkles for a long time, and can further improve the whole skin and increase the skin luster.
The invention comprises the following components in percentage by mass: 0.75% plant extract and 5% polypeptide mixture.
Within the above ratio range, the plant extract and the polypeptide mixture have an optimal synergistic firming-promoting effect.
As a preferred embodiment of the invention, the eye-tightening essence further comprises the following whitening components in percentage by mass: 1-5% of nicotinamide.
Niacinamide, also known as vitamin B3, is widely found in various animals and plants; has skin whitening, antiaging, moisture keeping, oil controlling, and skin barrier effects.
As a preferred embodiment of the invention, the eye tightening essence further comprises the following anti-inflammatory components in percentage by mass: 0.1 to 0.5% dipotassium glycyrrhizinate and 0.1 to 1% hydroxyphenylpropionamide benzoic acid.
The dipotassium glycyrrhizinate is used as a skin conditioner, and is mainly composed of glycyrrhizin (glycyrrhizic acid) at the root and stem of liquorice, which is suitable for allergic skin, has the functions of resisting irritation, controlling oil, reducing redness and swelling, diminishing inflammation and healing. Can effectively prevent sensitive inflammation phenomenon when skin is stimulated; the hydroxyphenylpropionamide benzoic acid has antihistaminic, anti-irritant and antipruritic effects. Can effectively inhibit skin erythema, edema and pruritus caused by histamine.
As a preferred embodiment of the present invention, the eye tightening essence further comprises the following moisturizers in percentage by mass: 2-5% of bioglycan-1, 2-8% of glycerol, 3-5% of butanediol and 0.5-2% of 1, 2-hexanediol.
Biopolysaccharide gum-1, alternative name: fucoidan, fucoidan sulfate; is a novel moisturizer, wrinkle remover, skin repair agent and skin feel modifier.
As a preferred embodiment of the present invention, the eye-tightening essence further comprises the following thickeners in percentage by mass: 0.1-0.5% of carbomer and 0.1-0.5% of acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer.
Acrylic acid (ester)/C10-30 alcohol acrylate cross-linked polymer sodium is used as film forming agent, and can be used as thickener and stabilizer in cosmetics; the formed film may also provide a water-locking function to the product.
As a preferred embodiment of the present invention, the eye-tightening essence further comprises the following pH adjusting agents in percentage by mass: 0.1-0.5% tromethamine and 0.01-0.1% disodium EDTA.
As a preferred embodiment of the present invention, the eye-tightening essence further comprises the following preservatives in percentage by mass: 0.1-0.5% of p-hydroxyacetophenone.
As a preferred embodiment of the invention, the eye tightening essence consists of the following components in percentage by mass: 0.75% of plant extract, 5% of polypeptide mixture, 3% of nicotinamide, 0.1-0.2% of dipotassium glycyrrhizinate, 0.3% of hydroxyphenylpropionamide benzoic acid, 2-3% of bioglycan-1, 5% of glycerol, 3% of butanediol, 0.5% of 1, 2-hexanediol, 0.2% of carbomer, 0.3% of acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% of tromethamine, 0.05% of disodium EDTA, 0.5% of p-hydroxyacetophenone and the balance of deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The invention also provides a preparation method of the eye tightening essence, which comprises the following steps:
(1) weighing deionized water, EDTA disodium, butanediol, glycerol, acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, p-hydroxyacetophenone and carbomer, mixing well, adding into a water phase pot, heating to 85 + -2 deg.C, stirring and dissolving well;
(2) cooling the mixture obtained in the step (1), and adding tromethamine;
(3) adding the plant extract, the polypeptide mixture, dipotassium glycyrrhizinate, nicotinamide, bioglycan-1 and 1, 2-hexanediol, stirring uniformly, and discharging after the inspection is qualified.
As a preferred embodiment of the present invention, tromethamine is added after the cooling of step (2) to 40 ℃.
The eye tightening essence disclosed by the invention is safe and non-irritant in components, can form a better barrier effect by adopting a plant extract mixture consisting of Kappaphycus alvarezii extract and Caesalpinia spinosa extract, can resist pollutants, irritants and allergens, and improve the biomechanical properties of skin, is compounded with polypeptide, and obtains a synergistic effect in the aspect of tightening effect by selecting a specific dosage ratio,
Detailed Description
To better illustrate the objects, aspects and advantages of the present invention, the present invention will be further described with reference to specific examples.
In the examples of the present invention, the raw materials were purchased from the market, wherein the plant extract (mixture of kappaphycus alvarezii extract and tara spinosa extract) was purchased from the company SILAB, with a product model of-filxel; the polypeptide mixture (mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7) is purchased from Sederma corporation, product type-
3000A; nicotinamide available from DSM as Niacinamide PC; bio-chicle-1 is purchased from Xianting corporation, product number FUCOGEL 1.5P; acrylic acid (ester)/C10-30 alkanol acrylate crosslinked polymer is purchased from Luborun Special chemical company, and the product type is-
ETD 2020Polymer。
Example 1
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 0.1% plant extract, 1% polypeptide mixture, 3% nicotinamide, 0.1% dipotassium glycyrrhizinate, 0.3% hydroxyphenylpropionamide benzoic acid, 2% bioglycan-1, 5% glycerol, 3% butanediol, 0.5% 1, 2-hexanediol, 0.2% carbomer, 0.2% acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% tromethamine, 0.05% disodium EDTA, 0.5% p-hydroxyacetophenone, and the balance deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The preparation method of the eye tightening essence comprises the following steps:
(1) weighing deionized water, EDTA disodium, butanediol, glycerol, acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, p-hydroxyacetophenone and carbomer, mixing well, adding into a water phase pot, heating to 85 + -2 deg.C, stirring and dissolving well;
(2) when the mixture in the step (1) is cooled to 40 ℃, adding tromethamine;
(3) adding the plant extract, the polypeptide mixture, dipotassium glycyrrhizinate, nicotinamide, bioglycan-1 and 1, 2-hexanediol, stirring uniformly, and discharging after the inspection is qualified.
Example 2
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 0.3% plant extract, 2% polypeptide mixture, 3% nicotinamide, 0.1% dipotassium glycyrrhizinate, 0.3% hydroxyphenylpropionamide benzoic acid, 2% bioglycan-1, 5% glycerol, 3% butanediol, 0.5% 1, 2-hexanediol, 0.2% carbomer, 0.2% acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% tromethamine, 0.05% disodium EDTA, 0.5% p-hydroxyacetophenone, and the balance deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Example 3
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 0.5% plant extract, 3% polypeptide mixture, 3% nicotinamide, 0.1% dipotassium glycyrrhizinate, 0.3% hydroxyphenylpropionamide benzoic acid, 2% bioglycan-1, 5% glycerol, 3% butanediol, 0.5% 1, 2-hexanediol, 0.2% carbomer, 0.35% acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% tromethamine, 0.05% disodium EDTA, 0.5% p-hydroxyacetophenone, and the balance deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Example 4
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 0.6% plant extract, 4% polypeptide mixture, 3% nicotinamide, 0.1% dipotassium glycyrrhizinate, 0.3% hydroxyphenylpropionamide benzoic acid, 2% bioglycan-1, 5% glycerol, 3% butanediol, 0.5% 1, 2-hexanediol, 0.2% carbomer, 0.3% acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% tromethamine, 0.05% disodium EDTA, 0.5% p-hydroxyacetophenone, and the balance deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Example 5
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 0.7% of plant extract, 5% of polypeptide mixture, 3% of nicotinamide, 0.1% of dipotassium glycyrrhizinate, 0.3% of hydroxyphenylpropionamide benzoic acid, 2% of bioglucan-1, 5% of glycerol, 3% of butanediol, 0.5% of 1, 2-hexanediol, 0.2% of carbomer, 0.3% of acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% of tromethamine, 0.05% of disodium EDTA, 0.5% of p-hydroxyacetophenone and the balance of deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Example 6
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 0.75% of plant extract, 5% of polypeptide mixture, 3% of nicotinamide, 0.1% of dipotassium glycyrrhizinate, 0.3% of hydroxyphenylpropionamide benzoic acid, 2% of bioglucan-1, 5% of glycerol, 3% of butanediol, 0.5% of 1, 2-hexanediol, 0.2% of carbomer, 0.3% of acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% of tromethamine, 0.05% of disodium EDTA, 0.5% of p-hydroxyacetophenone and the balance of deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Example 7
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 0.75% of plant extract, 5% of polypeptide mixture, 3% of nicotinamide, 0.2% of dipotassium glycyrrhizinate, 0.3% of hydroxyphenylpropionamide benzoic acid, 3% of bioglycan-1, 5% of glycerol, 3% of butanediol, 0.5% of 1, 2-hexanediol, 0.2% of carbomer, 0.3% of acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% of tromethamine, 0.05% of disodium EDTA, 0.5% of p-hydroxyacetophenone and the balance of deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Example 8
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 0.9% of plant extract, 5% of polypeptide mixture, 3% of nicotinamide, 0.3% of dipotassium glycyrrhizinate, 0.3% of hydroxyphenylpropionamide benzoic acid, 3% of bioglycan-1, 5% of glycerol, 3% of butanediol, 0.5% of 1, 2-hexanediol, 0.2% of carbomer, 0.3% of acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% of tromethamine, 0.05% of disodium EDTA, 0.5% of p-hydroxyacetophenone and the balance of deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Example 9
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 1% of plant extract, 5% of polypeptide mixture, 3% of nicotinamide, 0.4% of dipotassium glycyrrhizinate, 0.3% of hydroxyphenylpropionamide benzoic acid, 3% of bioglycan-1, 5% of glycerol, 3% of butanediol, 0.5% of 1, 2-hexanediol, 0.2% of carbomer, 0.3% of acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% of tromethamine, 0.05% of disodium EDTA, 0.5% of p-hydroxyacetophenone and the balance of deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Example 10
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 1% of plant extract, 5% of polypeptide mixture, 1% of nicotinamide, 0.5% of dipotassium glycyrrhizinate, 0.1% of hydroxyphenylpropionamide benzoic acid, 5% of bioglycan-1, 2% of glycerol, 5% of butanediol, 1% of 1, 2-hexanediol, 0.5% of carbomer, 0.1% of acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.5% of tromethamine, 0.1% of disodium EDTA, 0.5% of p-hydroxyacetophenone and the balance of deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Example 11
In an embodiment of the eye-tightening essence, the eye-tightening essence comprises the following components in percentage by mass: 1% of plant extract, 5% of polypeptide mixture, 5% of nicotinamide, 0.5% of dipotassium glycyrrhizinate, 1% of hydroxyphenylpropionamide benzoic acid, 3% of bioglycan-1, 8% of glycerol, 4% of butanediol, 2% of 1, 2-hexanediol, 0.1% of carbomer, 0.5% of acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.1% of tromethamine, 0.01% of disodium EDTA, 0.1% of p-hydroxyacetophenone and the balance of deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Comparative example 1
The eye tightening essence comprises the following components in percentage by mass: 5% polypeptide mixture, 3% nicotinamide, 0.1% dipotassium glycyrrhizinate, 0.3% hydroxyphenylpropionamide benzoic acid, 3% bioglycan-1, 5% glycerol, 3% butanediol, 0.5% 1, 2-hexanediol, 0.2% carbomer, 0.3% acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% tromethamine, 0.05% disodium EDTA, 0.5% p-hydroxyacetophenone, and the balance deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Comparative example 2
The eye tightening essence comprises the following components in percentage by mass: 1% polypeptide mixture, 3% nicotinamide, 0.1% dipotassium glycyrrhizinate, 0.3% hydroxyphenylpropionamide benzoic acid, 3% bioglycan-1, 5% glycerol, 3% butanediol, 0.5% 1, 2-hexanediol, 0.2% carbomer, 0.3% acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% tromethamine, 0.05% disodium EDTA, 0.5% p-hydroxyacetophenone, and the balance deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
The eye tightening essence was prepared in the same manner as in example 1.
Example 12 wrinkle resistance test
Female patients between 45 and 65 years old are randomly divided into 13 groups, each group is divided into 30 persons (without age), the 13 groups of patients try out the examples 1 to 11 and the comparative examples 1 and 2 respectively once every morning and evening, then the condition of the effect of each group is counted, the effect that the fish tail has less phenomena is obvious, the fine lines are gradually reduced in the circumference of eyes, and the result is shown in the table 1.
TABLE 1 anti-wrinkle test results
| Group of | Number of people | Number of effective people | Number of effective persons | Display efficiency | High efficiency |
| Example 1 | 30 | 15 | 12 | 50.00％ | 40.00％ |
| Example 2 | 30 | 18 | 15 | 60.00％ | 50.00％ |
| Example 3 | 30 | 16 | 15 | 53.33％ | 50.00％ |
| Example 4 | 30 | 23 | 20 | 76.67％ | 66.67％ |
| Example 5 | 30 | 25 | 20 | 83.33％ | 66.67％ |
| Example 6 | 30 | 28 | 26 | 93.33％ | 86.67％ |
| Example 7 | 30 | 28 | 26 | 93.33％ | 86.67％ |
| Example 8 | 30 | 27 | 22 | 90.00％ | 73.33％ |
| Example 9 | 30 | 27 | 23 | 90.00％ | 76.67％ |
| Example 10 | 30 | 23 | 19 | 76.67％ | 63.33％ |
| Example 11 | 30 | 23 | 18 | 76.67％ | 60.00％ |
| Comparative example 1 | 30 | 10 | 8 | 33.33％ | 26.67％ |
| Comparative example 2 | 30 | 12 | 9 | 40.00％ | 30.00％ |
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. The eye tightening essence is characterized by comprising the following components in percentage by mass: 0.1-1% of plant extract and 1-5% of polypeptide mixture; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
2. The eye tightening essence according to claim 1, comprising the following components in percentage by mass: 0.75% plant extract and 5% polypeptide mixture.
3. The eye tightening essence according to claim 1 or 2, further comprising the following whitening components in percentage by mass: 1-5% of nicotinamide.
4. The eye tightening essence according to claim 1 or 2, further comprising the following anti-inflammatory components in percentage by mass: 0.1 to 0.5% dipotassium glycyrrhizinate and 0.1 to 1% hydroxyphenylpropionamide benzoic acid.
5. The eye tightening essence according to claim 1 or 2, further comprising a humectant in the following mass percent: 2-5% of bioglycan-1, 2-8% of glycerol, 3-5% of butanediol and 0.5-2% of 1, 2-hexanediol.
6. The eye tightening essence according to claim 1 or 2, further comprising the following thickeners in percentage by mass: 0.1-0.5% of carbomer and 0.1-0.5% of acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer.
7. The eye tightening essence according to claim 1 or 2, further comprising the following pH adjusting agent in percentage by mass: 0.1-0.5% tromethamine and 0.01-0.1% disodium EDTA.
8. The eye tightening essence according to claim 1 or 2, further comprising the following preservatives in percentage by mass: 0.1-0.5% of p-hydroxyacetophenone.
9. The eye tightening essence according to claim 1 or 2, wherein the eye tightening essence consists of the following components in percentage by mass: 0.75% of plant extract, 5% of polypeptide mixture, 3% of nicotinamide, 0.1-0.2% of dipotassium glycyrrhizinate, 0.3% of hydroxyphenylpropionamide benzoic acid, 2-3% of bioglycan-1, 5% of glycerol, 3% of butanediol, 0.5% of 1, 2-hexanediol, 0.2% of carbomer, 0.3% of acrylic acid (ester)/C10-30 alkanol acrylate crosspolymer, 0.25% of tromethamine, 0.05% of disodium EDTA, 0.5% of p-hydroxyacetophenone and the balance of deionized water; the plant extract is a mixture of Kappaphycus alvarezii extract and Caesalpinia spinosa fruit extract, and the polypeptide mixture is a mixture of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7.
10. The eye tightening essence according to claim 9, comprising the steps of:
(1) weighing deionized water, EDTA disodium, butanediol, glycerol, acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, p-hydroxyacetophenone and carbomer, mixing well, adding into a water phase pot, heating to 85 + -2 deg.C, stirring and dissolving well;
(2) cooling the mixture obtained in the step (1), and adding tromethamine;
(3) adding the plant extract, the polypeptide mixture, dipotassium glycyrrhizinate, nicotinamide, bioglycan-1 and 1, 2-hexanediol, stirring uniformly, and discharging after the inspection is qualified.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011012499.XA CN112022734A (en) | 2020-09-23 | 2020-09-23 | Eye tightening essence and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011012499.XA CN112022734A (en) | 2020-09-23 | 2020-09-23 | Eye tightening essence and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112022734A true CN112022734A (en) | 2020-12-04 |
Family
ID=73575042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011012499.XA Pending CN112022734A (en) | 2020-09-23 | 2020-09-23 | Eye tightening essence and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112022734A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112494384A (en) * | 2020-12-09 | 2021-03-16 | 珠海为你而美丽化妆品有限公司 | Composition for removing dark eye circles, eye mask and preparation method of eye mask |
| CN112716853A (en) * | 2021-01-19 | 2021-04-30 | 广州市悦成生物科技有限公司 | Whitening composition and preparation method thereof |
| CN113749961A (en) * | 2021-09-01 | 2021-12-07 | 肽领生物科技(上海)有限公司 | 3D bionic plastic facial mask |
| CN113786376A (en) * | 2021-09-26 | 2021-12-14 | 湖北省麦诗特生物科技有限公司 | Eye cream composition with eyeprint removing effect and preparation method thereof |
| CN113786361A (en) * | 2021-09-26 | 2021-12-14 | 湖北省麦诗特生物科技有限公司 | Eye cream composition with pouch removing effect and preparation method thereof |
| CN117017874A (en) * | 2023-10-08 | 2023-11-10 | 铂臻(广州)生物科技有限公司 | Anti-wrinkle tightening face cream and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309236A (en) * | 2016-09-22 | 2017-01-11 | 上海新高姿化妆品有限公司 | Composition with anti-aging function and application thereof to cosmetics |
| CN110721148A (en) * | 2019-11-11 | 2020-01-24 | 奢脉国际化妆品(北京)有限公司 | Multidirectional pulling and tightening polypeptide essence and preparation method thereof |
-
2020
- 2020-09-23 CN CN202011012499.XA patent/CN112022734A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106309236A (en) * | 2016-09-22 | 2017-01-11 | 上海新高姿化妆品有限公司 | Composition with anti-aging function and application thereof to cosmetics |
| CN110721148A (en) * | 2019-11-11 | 2020-01-24 | 奢脉国际化妆品(北京)有限公司 | Multidirectional pulling and tightening polypeptide essence and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| LESSEL: "LESSEL新品 | 逆龄紧致眼霜", 《HTTPS://WWW.SOHU.COM/A/281795802_100203627?SPM=SMPC.AUTHOR.FD-D.33.1643267528723EA9UHSX》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112494384A (en) * | 2020-12-09 | 2021-03-16 | 珠海为你而美丽化妆品有限公司 | Composition for removing dark eye circles, eye mask and preparation method of eye mask |
| CN112716853A (en) * | 2021-01-19 | 2021-04-30 | 广州市悦成生物科技有限公司 | Whitening composition and preparation method thereof |
| CN113749961A (en) * | 2021-09-01 | 2021-12-07 | 肽领生物科技(上海)有限公司 | 3D bionic plastic facial mask |
| CN113786376A (en) * | 2021-09-26 | 2021-12-14 | 湖北省麦诗特生物科技有限公司 | Eye cream composition with eyeprint removing effect and preparation method thereof |
| CN113786361A (en) * | 2021-09-26 | 2021-12-14 | 湖北省麦诗特生物科技有限公司 | Eye cream composition with pouch removing effect and preparation method thereof |
| CN113786361B (en) * | 2021-09-26 | 2024-01-26 | 湖北省麦诗特生物科技有限公司 | Eye cream composition with pouch removing effect and preparation method thereof |
| CN113786376B (en) * | 2021-09-26 | 2024-02-23 | 湖北省麦诗特生物科技有限公司 | Eye cream composition with eye pattern removing effect and preparation method thereof |
| CN117017874A (en) * | 2023-10-08 | 2023-11-10 | 铂臻(广州)生物科技有限公司 | Anti-wrinkle tightening face cream and preparation method thereof |
| CN117017874B (en) * | 2023-10-08 | 2023-12-05 | 铂臻(广州)生物科技有限公司 | Anti-wrinkle tightening face cream and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112022734A (en) | Eye tightening essence and preparation method thereof | |
| CN110339115B (en) | Repair essence and preparation method thereof | |
| CN107334726B (en) | Acne-removing composition and preparation method and application thereof | |
| CN109106664A (en) | Have effects that moisturizing is releived the composition of maintenance, facial mask and preparation method thereof | |
| CN113648235B (en) | Composition for immediately removing wrinkles, eye mask essence, wrinkle-removing cosmetic and application | |
| CN110664716A (en) | Emulsifying system and application thereof, active composition and application thereof, cosmetic and preparation method | |
| CN109998937B (en) | Cosmetic series containing glycerol glucoside (alpha GG) and preparation method thereof | |
| CN110897941A (en) | Moisturizing and repairing composition with quicksand effect and preparation method thereof | |
| CN106619358A (en) | Skincare preparation with easing, anti-allergy and repairing effects | |
| CN111249195B (en) | Refreshing astringent lotion and preparation method thereof | |
| CN104288066A (en) | Smoothing toner and preparation method thereof | |
| CN111407698A (en) | Wrinkle-removing moisturizing skin care lotion and preparation method thereof | |
| CN108635275B (en) | Antioxidant composition and application thereof in essence | |
| CN111419751A (en) | Soothing composition, preparation method thereof and skin care product containing soothing composition | |
| CN105326696A (en) | Natural plant antioxidant essence milk and preparation method thereof | |
| CN109199923B (en) | Spray type sleeping mask and preparation method thereof | |
| CN107320357B (en) | Cosmetic containing polysaccharide | |
| CN113730321A (en) | Anti-wrinkle firming composition and application thereof in cosmetics | |
| CN113057925A (en) | A cosmetic containing herba Avenae Fatuae extract | |
| CN108815002B (en) | Skin care product and hair care product containing water-soluble ceramide | |
| CN110897905A (en) | Ginseng eye nutrition essence and preparation method thereof | |
| CN110787106A (en) | Plant revitalizing and purifying composition and preparation method thereof | |
| CN115569079A (en) | Moisturizing and oil-controlling essence and preparation method and application thereof | |
| CN115006303A (en) | Anti-allergy moisturizing skin-activating essence lotion and preparation method thereof | |
| CN112675094A (en) | Plant extract, repairing composition, skin care product and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201204 |
|
| RJ01 | Rejection of invention patent application after publication |